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Impact of bone marrow
fibrosis grade in post-
polycythemia vera and post-
essential thrombocythemia
myelofibrosis: A study of the
MYSEC group
To the Editor:
Polycythemia vera (PV) and essential thrombocythemia (ET) are myelo-
proliferative neoplasms that can progress to post-PV (PPV-) myelofibro-
sis (MF) and post-ET (PET-) MF, also known as secondary myelofibrosis
(SMF). The 2008 diagnostic criteria for SMF require the presence of sig-
nificant bone marrow fibrosis (BMF). The impact of BMF grading on
presentation and outcome in primary MF (PMF) has been extensively
explored,1-3 while only limited information is available in SMF.4
For this reason, we analyzed the MYSEC (MYelofibrosis SECondary
to PV and ET) cohort, recently updated, now including 805 SMF
patients among 17 centers in Europe and United States.5
The SMF diagnoses were performed between 1981 and 2017. Par-
ticular attention was given in order to avoid the inclusion of pre-fibrotic
MF. BMF at time of SMF evolution was semi-quantitatively defined as
grade 2 (BMF2) in case of a diffuse increase in reticulin with extensive
intersections, occasional bundles of collagen and/or osteosclerosis, or
as grade 3 (BMF3) if presenting with coarse bundles of collagen, often
associated with osteosclerosis. Chi-square or Fisher exact test for cate-
gorical variables and Wilcoxon rank-sum test for continuous ones were
applied for exploring patterns of association between BMF grading and
patients’ characteristics. Multiple logistic regression analysis was used
for the same purpose, and adjusted odds ratio together with 95% Con-
fidence Interval (95% CI) were calculated. Rates of events were evalu-
ated with a Poisson regression model. Survival curves were estimated
using the Kaplan-Meier method and log-rank test was calculated. A Cox
proportional hazard regression model was applied for multivariate sur-
vival analysis. The MYSEC study was approved by the Review Board of
each Institution, and conducted in accordance with the Declaration of
Helsinki.
Detailed information on BMF grading was available in 675 MYSEC
patients: BMF2 was reported in 443 (65.6%) and BMF3 in 232 (34.4%).
At SMF diagnosis, we did not find any correlation between BMF grade
and age, gender, time to progression from PV/ET, spleen and liver size,
presence of constitutional symptoms and marrow blast percentage
(Table S1). No relationship was noticed with abnormal karyotype
(stratified as previously reported)6 with data available in about 50% of
the cohort (Table S1). Looking at genotype, BMF grading was not differ-
ently distributed among the three driver mutations as well as in “triple
negative” cases (Table S1).
On the contrary, in univariate analysis, there was a significant asso-
ciation between BMF3 and previous diagnosis of ET (P = .02),
decreased hemoglobin levels (P < .0001), reduced platelet (P < .0001)
and leukocyte counts (P = .001), higher percentage of circulating blasts
(P = .01) and LDH value (P = .001) (Table S1). In multivariate analysis,
BMF3 resulted significantly correlated with previous ET (P = .006),
lower hemoglobin level (P = .0002) and reduced platelet count
(P = .0006) (Table S2). Patients with BMF2 were more frequently
included in the lower MYSEC-PM (MYSEC-Prognostic Model) risk
groups, while those with BMF3 were enriched in the higher risk catego-
ries (P < .0001, Table S1).
Median follow-up of the cohort was 11.0 (range, 0.6-41.4) years
from ET/PV phase to SMF and 3.1 (range, 0.6-27) years after SMF
transformation. More patients with BMF2 received cytoreductive
therapies during the course of SMF (P < .0001; Table S1). On the con-
trary, more patients with BMF3 underwent allogenic stem cells trans-
plantation (P < .0001, Table S1).
No differences were noticed in terms of cumulative incidence of
thrombosis between BMF subgroups (Table S3). Evolution into post-
SMF blast phase was documented in 62 (9.2%) patients, without any
effect of BMF grade (Table S3).
We found a significantly higher mortality in case of BMF3 vs BMF2
(P < .0001, Table S3). Median survival was 8.2 (95% CI: 7.7-11.8) years
in the BMF2 subgroup, while it corresponded to 7.4 (95% CI: 5.1-10.1)
years for BMF3 (P = .011, Figure 1). Nevertheless, when adjusting the-
impact of BMF3 grade on survival in a Cox multivariate analysis
that considered MYSEC-PM categories (low and intermediate-1 vs
intermediate-2 and high), the BMF grade lost its prognostic rele-
vance (P = .13).
Our study provides evidence that BMF grade is associated with a
specific phenotype in SMF. Multivariate analysis showed that BMF3
clustered with lower hemoglobin and reduced platelet values. Similarly,
recent papers on PMF demonstrated that blood count counts are
inversely correlated with BMF grade.1,3 In our cohort of 675 SMF
patients, BMF3 was significantly associated with PET- vs PPV-MF,
irrespectively of previous ET/PV duration. Another study on 755 PMF
and 344 SMF reported that “advanced” BMF grades (2, 3) are more fre-
quent in PPV-MF than in PET-MF or PMF.4 This result could be
explained by the fact that even cases with BMF grade lower than 2 were
retrospectively included among those 344 SMF.4 In our dataset, BMF3
clustered with intermediate-2 and high MYSEC-PM categories and detri-
mental SMF outcome. Likewise, higher IPSS (International Prognostic Scor-
ing System) subgroups were enriched by PMF cases with a more
advanced BMF, and a consequently worse survival.3
Received: 22 August 2019 Revised: 16 September 2019 Accepted: 20 September 2019
DOI: 10.1002/ajh.25644
Am J Hematol. 2020;95:E1–E30. wileyonlinelibrary.com/journal/ajh © 2019 Wiley Periodicals, Inc. E1
In our SMF cohort, BMF3 resulted associated with a significant
lower use of cytoreductive therapies and a higher rate of allogenic
stem cells transplantation. It might be plausible that the less myelo-
proliferative phenotype and the expected worse outcome of these
patients had influenced physicians’ treatment decision.
Available information indicates that BMF grade has a different
impact on PMF- vs SMF-specific prognostic scoring systems. In PMF,
BMF grading provided additional information to IPSS and was recently
included in the MIPSS70 (Mutation-Enhanced IPSS for patients aged
less than 70 years) score.2,3 Differently, BMF did not implement SMF
survival prediction as defined by the MYSEC-PM.5 It will be of interest
to see if BMF3 clusters with “unfavorable” additional mutations in
myeloid genes, as pointed out in a study on PMF.3
In conclusion, the development of progressive anemia and throm-
bocytopenia during the course of PV and ET, besides suggesting an
evolution into SMF, might be also a surrogate of BMF3 grade, eventu-
ally resulting in a worse outcome. This suggests to monitor carefully
cell blood count in PV and ET patients, with the aim to detect early a
possible transformation into SMF.
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Bone marrow blast
elimination by the fifth day of
7 + 3 induction is the
strongest predictor of
potential cure in patients with
acute myeloid leukemia
younger than 61 years of age:
A long-term follow-up of a
multi-center prospective
study
To the Editor:
Multiple clinical and genomic factors have been shown to be asso-
ciated with improved prognosis in acute myeloid leukemia (AML).
Nevertheless, based on the recent European LeukemiaNet (ELN)
guidelines, incorporating these features,1 a significant portion of
younger patients presenting with de-novo AML are still catego-
rized in the intermediate-risk group. Refined precision of the out-
come prediction is essential for the assignment of such patients to
treatment, particularly allogeneic stem cell transplantation
(allo-SCT).
Rapid eradication of blasts from the peripheral blood during
induction therapy for AML is associated with a good response to ini-
tial treatment.2-4 Our previously conducted prospective observational
study has aimed to identify the subgroup of leukemic patients in
whom a prompt response to therapy would be a surrogate for a supe-
rior outcome. The findings of the study have demonstrated that early
bone marrow (BM) response, defined as reduction in the number of
BM blasts to less than 5% of BM cells by the fifth day of induction is a
strong predictor of remission and improved OS5 in patients younger
than 61 years old and/or those with non-adverse cytogenetics, receiv-
ing the 3 + 7 induction regimen.
We herein report the results of prolonged prospective follow-up of
a median of 64 months (range 17.5-96) demonstrating that among AML
patients younger than 61 years of age, clearance of BM blasts to less
than 5% by the fifth day of induction is not only the strongest predictor
of good prognosis, but is also a promising marker for cure. Notably, our
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